<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331838</url>
  </required_header>
  <id_info>
    <org_study_id>DRI6243</org_study_id>
    <secondary_id>2005-006202-26</secondary_id>
    <nct_id>NCT00331838</nct_id>
  </id_info>
  <brief_title>Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery</brief_title>
  <acronym>TREK</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose Response Study of Subcutaneous AVE5026 With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026)
      for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee
      replacement [TKR] surgery.

      Secondary objectives were to evaluate the safety (incidence of major bleeding) of AVE5026, to
      document the efficacy and safety of AVE5026 post-operative regimens, and to assess the
      pharmacokinetic parameters of AVE5026.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The randomization had to take place before the first study drug injection.

      The total duration of observation per participant was 27-33 days from surgery broken down as
      follows:

        -  4 to 10-day double-blind treatment period;

        -  Follow-up period up to Day 30 ± 3 after surgery.

      Mandatory bilateral venography of the lower limbs had to be performed between 5 to 11 days
      after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Venous Thromboembolism Event (VTE) or VTE-related Death</measure>
    <time_frame>From surgery to Day 11 or the day of mandatory venography, whichever came first</time_frame>
    <description>VTE included any Deep Vein Thrombosis [DVT] identified on mandatory venography of the lower limbs; symptomatic DVT and/or non-fatal pulmonary embolism [PE] before mandatory examination; VTE related deaths included fatal PE or deaths which could not be attributed to a documented cause and for which PE could not be ruled out. All events were to be confirmed by a Central Independent Adjudication Committee [CIAC] based on venographies, scheduled or unscheduled, and other available diagnostic tests (ultrasonography, ventilation/perfusion lung scan, pulmonary angiography, autopsy report, etc).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced DVT</measure>
    <time_frame>From surgery up to Day 11 or the day of mandatory venography, whichever came first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Symptomatic VTE</measure>
    <time_frame>From surgery up to Day 11 or the day of mandatory venography, whichever came first</time_frame>
    <description>Symptomatic VTE included:
suspected DVT confirmed by the CIAC based on compression ultrasonography or venography;
suspected PE confirmed by the CIAC based on perfusion/ventilation lung scan, pulmonary angiography or spiral computerized tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Bleedings</measure>
    <time_frame>From 1st study drug injection up to 3 days after last study drug injection (median duration of approximately 11 days)</time_frame>
    <description>Bleedings were centrally and blindly reviewed by the CIAC and classified as:
&quot;Major&quot; (fatal bleeding, bleeding that was retroperitoneal or intracranial or that involved any other critical organ (e.g. eye, adrenal gland, pericardium or spine), surgical site bleeding leading to intervention, non-surgical site bleeding requiring surgical intervention or with a bleeding index ≥2);
&quot;Minor&quot; (overt bleeding considered more than expected but not meeting the criteria for major bleeding);
&quot;Criteria for bleeding event not satisfied&quot; (not meeting the criteria for major or minor bleeding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Initiation of Curative Anticoagulant or Thrombolytic Treatment After VTE Assessment</measure>
    <time_frame>From surgery up to Day 11 or the day of mandatory venography, whichever came first</time_frame>
    <description>Initiation of curative anticoagulant or thrombolytic treatment after VTE assessment was defined from investigator's answers to questions asked after diagnostic tests for suspected VTE and/or the mandatory venography.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>From 1st study drug injection up to 3 days after last study drug injection (median duration of approximately 11 days)</time_frame>
    <description>All deaths were centrally and blindly reviewed by the CIAC and classified as &quot;Fatal PE&quot;, &quot;PE not excluded&quot;, &quot;Fatal bleeding&quot; and &quot;Death not associated with VTE or bleeding&quot; based on relevant documentation (e.g. autopsy report).</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelets Count: Number of Participants With Potentially Clinically Significant Abnormalities [PCSA]</measure>
    <time_frame>From 1st study drug injection up to 3 days after last study drug injection (median duration of approximately 11 days)</time_frame>
    <description>PCSA are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review. Threshold for platelet counts was defined as &lt;100 Giga/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver Function: Number of Participants With Potentially Clinically Significant Abnormalities [PCSA]</measure>
    <time_frame>From 1st study drug injection up to 3 days after last study drug injection (median duration of approximately 11 days)</time_frame>
    <description>Thresholds were defined as follows:
Alanine Aminotransferase [ALAT] &gt;3 Upper Normal Limit [ULN];
Total Bilirubin [TB] ≥34 μmol/L;
ALAT ≥3 ULN and TB ≥34 μmol/L.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">705</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Semuloparin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semuloparin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semuloparin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semuloparin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semuloparin 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pre-op / Semuloparin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,
Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pre-op / Semuloparin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,
Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semuloparin sodium</intervention_name>
    <description>0.8 mL solution in Type I amber glass vials
Subcutaneous injection</description>
    <arm_group_label>Semuloparin 5 mg</arm_group_label>
    <arm_group_label>Semuloparin 10 mg</arm_group_label>
    <arm_group_label>Semuloparin 20 mg</arm_group_label>
    <arm_group_label>Semuloparin 40 mg</arm_group_label>
    <arm_group_label>Semuloparin 60 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 20 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 40 mg</arm_group_label>
    <other_name>AVE5026</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Enoxaparin sodium)</intervention_name>
    <description>0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection</description>
    <arm_group_label>Semuloparin 5 mg</arm_group_label>
    <arm_group_label>Semuloparin 10 mg</arm_group_label>
    <arm_group_label>Semuloparin 20 mg</arm_group_label>
    <arm_group_label>Semuloparin 40 mg</arm_group_label>
    <arm_group_label>Semuloparin 60 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 20 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin sodium</intervention_name>
    <description>0.4 mL solution in ready-to-use pre-filled syringe
Subcutaneous injection</description>
    <arm_group_label>Enoxaparin 40 mg</arm_group_label>
    <other_name>Lovenox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Semuloparin sodium)</intervention_name>
    <description>0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component
Subcutaneous injection</description>
    <arm_group_label>Enoxaparin 40 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 20 mg</arm_group_label>
    <arm_group_label>Placebo pre-op / Semuloparin 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient scheduled to undergo elective total knee replacement or revision of a primary
             procedure performed ≥ 6 months prior to study entry.

        Exclusion Criteria:

          -  Any major orthopedic surgery in the 3 months prior to study entry;

          -  Clinical signs or symptoms of DVT or PE within the last 12 months or known
             post-phlebitic syndrome;

          -  Known sensitivity to iodine or contrast dyes;

          -  Recent stroke or myocardial infarction;

          -  High risk of bleeding;

          -  Treatment with other anti-thrombotic agents within 7 days prior to surgery;

          -  Any contra-indication to Unfractionated Heparin or Low Molecular Weight Heparin;

          -  Pregnant or nursing woman, or woman of childbearing potential who is not using an
             effective contraceptive method.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael LASSEN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hoersholm Hospital (Denmark)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santafe de Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Spain</country>
  </removed_countries>
  <results_reference>
    <citation>Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. J Thromb Haemost. 2009 Apr;7(4):566-72. doi: 10.1111/j.1538-7836.2009.03301.x. Epub 2009 Jan 24.</citation>
    <PMID>19187076</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Venous Thrombosis</keyword>
  <keyword>Orthopedic Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

